Results 11 to 20 of about 5,054 (206)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab [PDF]

Dermatology and Therapy, 2023
Guselkumab is an anti-interleukin-23 monoclonal antibody that is approved for plaque psoriasis and psoriatic arthritis. We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn.
Erin Bartholomew, Bo-Young Chung, Mitchell Davis, Samuel Yeroushalmi, Mimi Chung, Marwa Hakimi, Tina Bhutani, Wilson Liao   +7 more
doaj   +2 more sources

Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling [PDF]

Frontiers in Immunology
IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue.
Kacey L. Sachen, Deepa Hammaker, Indra Sarabia, Brian Stoveken, John Hartman, Kristin L. Leppard, Nicholas A. Manieri, Phuc Bao, Carrie Greving, Eilyn R. Lacy, Matthew DuPrie, Joshua Wertheimer, Janise D. Deming, Joseph Brown, Amy Hart, He (Hurley) Li, Tom C. Freeman, Brice Keyes, Kristen Kohler, Ian White, Nathan Karpowich, Ruth Steele, M. Merle Elloso, Steven Fakharzadeh, Kavitha Goyal, Frédéric Lavie, Maria T. Abreu, Matthieu Allez, Raja Atreya, Robert Bissonnette, Kilian Eyerich, Kilian Eyerich, James G. Krueger, Dennis McGonagle, Iain B. McInnes, Christopher Ritchlin, Anne M. Fourie   +36 more
doaj   +3 more sources

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study [PDF]

RMD Open, 2020
Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA).Methods This was a phase II, randomised, placebo-controlled, double-blind trial of adults with active PsA ...
Peter Nash, Atul Deodhar, Philip J Mease, Dafna D Gladman, Philip S Helliwell, Dennis G McGonagle, Alice Gottlieb, Elizabeth C Hsia, Chetan S Karyekar, Wolf-Henning Boehncke, Xie L Xu, Stephen Xu   +11 more
doaj   +2 more sources

Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison [PDF]

Anais Brasileiros de Dermatologia
Background: Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune component, often treated with immunomodulators such as biologic therapies.
Leyla Baykal Selçuk, Hande Ermiş Akkuş, Burak Akşan, Deniz Aksu Arıca   +3 more
doaj   +2 more sources

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study [PDF]

, 2023
BACKGROUND & AIMS: The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or ...
Shipitofsky, N, Germinaro, M, Bressler, B, Wilson, R, Han, C, Huang, K-HG, Zhang, H, Allegretti, JR, Peyrin-Biroulet, L, Rubin, DT   +9 more
core   +5 more sources

Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study [PDF]

ACR Open Rheumatology
Objective Group‐level analyses from the phase 3 DISCOVER‐2 trial of guselkumab demonstrated robust and durable improvements across psoriatic arthritis (PsA) domains.
Philip J. Mease, Xenofon Baraliakos, Vinod Chandran, Enrique R. Soriano, Peter Nash, Atul Deodhar, Emmanouil Rampakakis, Natalie J. Shiff, Soumya D. Chakravarty, May Shawi, Joseph F. Merola, Iain B. McInnes   +11 more
doaj   +2 more sources

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis [PDF]

, 2021
Guselkumab, a subcutaneously administered fully human IgG1λ monoclonal antibody that selectively inhibits the p19 subunit of interleukin 23, is approved in both the USA and the EU for the treatment of adult patients with moderate-to-severe plaque ...
Parodi, Aurora, Bardazzi, Federico, De Simone, Clara, Amerio, Paolo, Carrera, Carlo Giovanni, Talamonti, Marina, Lo Schiavo, Ada, Argenziano, Giuseppe, Dapavo, Paolo, Rongioletti, Franco, Loconsole, Francesco, Peris, Ketty, Prignano, Francesca, Conti, Andrea, Potenza, Concetta, Musumeci, Maria Letizia, Malagoli, Piergiorgio, Costanzo, Antonio, Balato, Nicola, Malara, Giovanna, Chiricozzi, Andrea, Fargnoli, Maria Concetta, Piaserico, Stefano, Bianchi, Luca   +23 more
core   +2 more sources

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. [PDF]

, 2021
OBJECTIVE: The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic arthritis (PsA) has recently been demonstrated in two phase 3 trials (DISCOVER-1 & -2) but has not been evaluated vs other targeted therapies for PsA.
Tam, Lai-Shan, Ritchlin, Christopher, Karyekar, Chetan S, Nair, Sandhya, Boehncke, Wolf-Henning, McInnes, Iain B, Parackal, Anna, Peterson, Steve, Eaton, Kiefer, Chakravarty, Soumya D, Mease, Philip J, Schubert, Agata   +11 more
core   +3 more sources

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

Trials, 2023
Background Guselkumab, a fully human monoclonal antibody targeting the interleukin (IL)-23p19 subunit, is approved to treat adults with active psoriatic arthritis (PsA).
Christopher T. Ritchlin, Laura C. Coates, Philip J. Mease, Désirée van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P. Kollmeier, Proton Rahman   +8 more
doaj   +1 more source

Guselkumab for the treatment of psoriasis - evidence to date [PDF]

, 2019
Psoriasis is a chronic, immune-mediated, inflammatory, and debilitating skin disease with significant impact on patients' quality of life. Its pathogenesis is complex and not yet fully understood. However, the IL-23/IL-17 axis is currently considered the
Torres, T., Nogueira, Miguel
core   +1 more source